Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02665065 · ClinicalTrials.gov registry record · Phase 3
Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia
A Phase 3 study of Acute Myeloid Leukemia and Acute Myelogenous Leukemia, sponsored by Actinium Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 153
- Enrollment target
- 20
- Study locations
NCT02665065: Active Phase 3 study of Acute Myeloid Leukemia and Acute Myelogenous Leukemia, sponsored by Actinium Pharmaceuticals.
NCT02665065 is a Phase 3 study of Acute Myeloid Leukemia and Acute Myelogenous Leukemia that is active but no longer recruiting, run by Actinium Pharmaceuticals. The registered enrollment target is 153 participants, above the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (33% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02665065, a Phase 3 study of Acute Myeloid Leukemia and Acute Myelogenous Leukemia, is active but no longer recruiting, sponsored by Actinium Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 153 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to demonstrate the efficacy of Iomab-B, in conjunction with a Reduced Intensity Conditioning (RIC) regimen and protocol-specified allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care in patients with Active, Relapsed or Refractory Acute Myeloid Leukemia (AML).
Primary Outcome
Defined as CR or CRp lasting 180 days or more from time of initial CR or CRp is documented with evidence of subsequent relapse
Conditions Studied
Interventions
- DRUG Iomab-B
- DRUG Conventional Care
- PROCEDURE HCT
Study Locations (20)
New York
- Roswell Park Cancer Institute - Buffalo
- Weill Cornell Medicine - New York
- Memorial Sloan Kettering Cancer Center - New York
- Stony Brook University - Stony Brook
Ohio
- University Hospital of Cleveland Seidman Cancer Center - Cleveland
- The Ohio State University Comprehensive Cancer Center - Columbus
Texas
- Baylor Charles A. Sammons Cancer Center - Dallas
- MD Anderson Cancer Center - Houston
Arizona
- Banner MD Anderson Cancer Center - Gilbert
Connecticut
- Yale Cancer Center - New Haven
District of Columbia
- Georgetown University Medical Center - Washington D.C.
Florida
- Mayo Clinic - Jacksonville
Illinois
- Loyola University Medical Center - Maywood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2016-06 |
| Est. Completion | 2026-12 |
| Phase | Phase 3 |
What the registry record for NCT02665065 still lists
NCT02665065 is an interventional study that assigns participants to a tested intervention. The registered 153 participants enrollment target is mid-sized for trials with a published cap, above the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (33% higher).
The record links to 9 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Iomab-B is the first listed.
NCT02665065 names 20 study sites across 15 states, led by New York, Ohio, Texas.
Frequently Asked Questions
What is clinical trial NCT02665065 about?
NCT02665065 is a clinical study titled "Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia". The primary objective of this study is to demonstrate the efficacy of Iomab-B, in conjunction with a Reduced Intensity Conditioning (RIC) regimen and protocol-specified allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care in patients with Active, Relapsed or Refractory Acute...
What is the current status of trial NCT02665065?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 153 participants. The study started on 2016-06. Estimated completion is 2026-12.
What conditions does trial NCT02665065 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia, Acute Myelogenous Leukemia, Leukemia, Myeloid, Acute, AML, Bone Marrow Transplant.
What interventions are being tested in trial NCT02665065?
The interventions under investigation include: Iomab-B (DRUG), Conventional Care (DRUG), HCT (PROCEDURE).
Who is sponsoring clinical trial NCT02665065?
This trial is sponsored by Actinium Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02665065 being conducted?
This trial has 20 study locations across Arizona, Connecticut, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02665065's enrollment target sits among peer trials
153 56th of 306 higher than 250 of 306 other Acute Myeloid Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Myeloid Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
RECRUITING · Phase 3
-
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
RECRUITING · Phase 3
-
Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome
ACTIVE NOT RECRUITING · Phase 3
-
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
ACTIVE NOT RECRUITING · Phase 3
-
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
ACTIVE NOT RECRUITING · Phase 3
-
Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05283265 · 153 participants · NA
Neurophysiological Mechanisms of Language Comprehension
- NCT05584501 · 153 participants · NA
ETE Interventions in the Dental Setting
- NCT05714839 · 153 participants · Phase 1
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
- NCT06293352 · 153 participants · NA
Real-component Vs All-cement Articulating Spacers for Periprosthetic Knee Infection
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia